(NASDAQ: ZYME) Zymeworks's forecast annual revenue growth rate of 36.11% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.48%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.37%.
Zymeworks's revenue in 2025 is $76,304,000.On average, 5 Wall Street analysts forecast ZYME's revenue for 2025 to be $6,242,855,404, with the lowest ZYME revenue forecast at $3,687,574,799, and the highest ZYME revenue forecast at $8,175,283,753. On average, 4 Wall Street analysts forecast ZYME's revenue for 2026 to be $13,767,873,608, with the lowest ZYME revenue forecast at $8,272,691,389, and the highest ZYME revenue forecast at $21,795,654,369.
In 2027, ZYME is forecast to generate $11,191,163,323 in revenue, with the lowest revenue forecast at $4,661,651,161 and the highest revenue forecast at $14,940,939,855.